Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

Published on Jan 4, 2019in Molecular Pharmaceutics4.321
· DOI :10.1021/ACS.MOLPHARMACEUT.8B00922
Sergey M. Deyev29
Estimated H-index: 29
(National Research Nuclear University MEPhI),
Anzhelika Vorobyeva11
Estimated H-index: 11
+ 10 AuthorsVladimir Tolmachev61
Estimated H-index: 61
Sources
Abstract
Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins that can be selected for binding to desirable molecular targets. High affinity and small size of DARPins render the ...
📖 Papers frequently viewed together
24 Citations
50 Citations
104 Citations
References0
Newest
#1Javad Garousi (Uppsala University)H-Index: 13
#2Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract ADAPTs are small engineered non-immunoglobulin scaffold proteins, which have demonstrated very promising features as vectors for radionuclide tumour targeting. Radionuclide imaging of human epidermal growth factor 2 (HER2) expression in vivo might be used for stratification of patients for HER2-targeting therapies. ADAPT6, which specifically binds to HER2, has earlier been shown to have very promising features for in vivo targeting of HER2 expressing tumours. In this study we tested the...
11 CitationsSource
#1Anzhelika Vorobyeva (Uppsala University)H-Index: 11
#2Olga Bragina (RAS: Russian Academy of Sciences)H-Index: 4
Last. Sergey M. Deyev (Tomsk Polytechnic University)H-Index: 29
view all 10 authors...
High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib). Radionuclide molecular imaging of HER2 expression might permit stratification of patients for HER2-targeting therapies. In this study, we evaluated a new HER2-imaging probe based on the designed ...
22 CitationsSource
#1Ahmet KrasniqiH-Index: 8
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 8 authors...
Imaging of expression of therapeutic targets may enable patients' stratification for targeted treatments. The use of small radiolabeled probes based on the heavy-chain variable region of heavy-chai ...
55 CitationsSource
#1Rudo Simeon (A&M: Texas A&M University)H-Index: 7
#2Zhilei Chen (A&M: Texas A&M University)H-Index: 17
Antibodies have proved to be a valuable mode of therapy for numerous diseases, mainly owing to their high target binding affinity and specificity. Unfortunately, antibodies are also limited in several respects, chief amongst those being the extremely high cost of manufacture. Therefore, non-antibody binding proteins have long been sought after as alternative therapies. New binding protein scaffolds are constantly being designed or discovered with some already approved for human use by the FDA. T...
73 CitationsSource
#1Dominik SummerH-Index: 10
#2Javad Garousi (Uppsala University)H-Index: 13
Last. Clemens DecristoforoH-Index: 53
view all 10 authors...
Zirconium-89 is an emerging radionuclide for positron emission tomography (PET) especially for biomolecules with slow e pharmacokinetics as due to its longer half-life, in comparison to fluorine 18 ...
20 CitationsSource
#1Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
#2Javad Garousi (Uppsala University)H-Index: 13
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 8 authors...
Visualization of cancer-associated alterations of molecular phenotype using radionuclide imaging is a noninvasive approach to stratifying patients for targeted therapies. The engineered albumin-bin ...
24 CitationsSource
Nonimmunoglobulin scaffolds have been developed to overcome the limitations of monoclonal antibodies with regard to stability and size. Of these scaffolds, the class of designed ankyrin repeat proteins (DARPins) has advanced the most in biochemical and biomedical applications. This review focuses on the recent progress in DARPin technology, highlighting the scaffold's potential and possibilities.
10 CitationsSource
#1Stefan Ståhl (KTH: Royal Institute of Technology)H-Index: 66
#2Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
Last. John Löfblom (KTH: Royal Institute of Technology)H-Index: 24
view all 6 authors...
Affibody molecules are small (6.5-kDa) affinity proteins based on a three-helix bundle domain framework. Since their introduction 20 years ago as an alternative to antibodies for biotechnological applications, the first therapeutic affibody molecules have now entered clinical development and more than 400 studies have been published in which affibody molecules have been developed and used in a variety of contexts. In this review, we focus primarily on efforts over the past 5 years to explore the...
110 CitationsSource
#1E. A. Sokolova (RAS: Russian Academy of Sciences)H-Index: 8
#2G. M. Proshkina (RAS: Russian Academy of Sciences)H-Index: 11
Last. Sergey M. Deyev (RAS: Russian Academy of Sciences)H-Index: 29
view all 10 authors...
Abstract DARPins fused with other proteins are promising non-immunoglobulin scaffolds for specific binding to target cells. In this study HER2-specific DARPin (DARPin_9–29) was used as a tumor-targeting moiety for the delivery of a cytotoxic agent – the fragment of Pseudomonas aeruginosa exotoxin A. It was determined that DARPin-PE40 possesses a considerable cytotoxic activity and induces apoptosis in HER2-positive cells. Cytotoxic effect of DARPin-PE40 strongly correlates with the HER2 expressi...
31 CitationsSource
#1Yvonne W. S. Jauw (VUmc: VU University Medical Center)H-Index: 7
#2C. Willemien Menke-van der Houven van Oordt (VUmc: VU University Medical Center)H-Index: 9
Last. Guus A.M.S. van Dongen (VUmc: VU University Medical Center)H-Index: 64
view all 8 authors...
Selection of the right drug for the right patient is a promising approach to increase clinical benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo biodistribution and tumor targeting of mAbs to predict toxicity and efficacy is expected to guide individualized treatment and drug development. Molecular imaging with positron emission tomography (PET) using zirconium-89 (89Zr)-labeled monoclonal antibodies also known as 89Zr-immuno-PET, visualizes and quantifies upta...
106 CitationsSource
Cited By16
Newest
#1Tianqi Xu (Uppsala University)H-Index: 2
#2Anzhelika Vorobyeva (Uppsala University)H-Index: 11
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 11 authors...
Efficient treatment of disseminated ovarian cancer (OC) is challenging due to its heterogeneity and chemoresistance. Overexpression of human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM) in approx. 30% and 70% of ovarian cancers, respectively, allows for co-targeted treatment. The clinical efficacy of the monoclonal antibody trastuzumab in patients with HER2-positive breast, gastric and gastroesophageal cancers makes it readily available as the HER2-targ...
Source
#1Sergey Deyev (Tomsk Polytechnic University)H-Index: 2
#2Tianqi Xu (Uppsala University)H-Index: 2
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 13 authors...
The epithelial cell adhesion molecule (EpCAM) is intensively overexpressed in 40–60% of prostate cancer (PCa) cases and can be used as a target for the delivery of drugs and toxins. The designed ankyrin repeat protein (DARPin) Ec1 has a high affinity to EpCAM (68 pM) and a small size (18 kDa). Radiolabeled Ec1 might be used as a companion diagnostic for the selection of PCa patients for therapy. The study aimed to investigate the influence of radiolabel position (N- or C-terminal) and compositio...
1 CitationsSource
#1Vladimir Tolmachev (Tomsk Polytechnic University)H-Index: 61
#2Anna Orlova (Tomsk Polytechnic University)H-Index: 53
Last. Jens Nørkær Sørensen (Uppsala University)H-Index: 66
view all 3 authors...
Abstract Targeting of human epidermal growth factor type 2 (HER2) using monoclonal antibodies, antibody-drug conjugates and tyrosine kinase inhibitors extends survival of patients with HER2-expressing metastatic breast cancer. High expression of HER2 is a predictive biomarker for such specific treatment. Accurate determination of HER2 expression level is necessary for stratification of patients to targeted therapy. Non-invasive in vivo radionuclide molecular imaging of HER2 has a potential of re...
1 CitationsSource
1 CitationsSource
#1Sara S. RinneH-Index: 8
#2Anna Orlova (Tomsk Polytechnic University)H-Index: 53
Last. Vladimir TolmachevH-Index: 61
view all 3 authors...
The human epidermal growth factor receptor family (EGFR-family, other designations: HER family, RTK Class I) is strongly linked to oncogenic transformation. Its members are frequently overexpressed in cancer and have become attractive targets for cancer therapy. To ensure effective patient care, potential responders to HER-targeted therapy need to be identified. Radionuclide molecular imaging can be a key asset for the detection of overexpression of EGFR-family members. It meets the need for rep...
Source
#1Javad Garousi (Uppsala University)H-Index: 13
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract Molecular recognition in targeted therapeutics is typically based on immunoglobulins. Development of engineered scaffold proteins (ESPs) has provided additional opportunities for the development of targeted therapies. ESPs offer inexpensive production in prokaryotic hosts, high stability and convenient approaches to modify their biodistribution. In this study, we demonstrated successful modification of the biodistribution of an ESP known as ADAPT (Albumin-binding domain Derived Affinity...
1 CitationsSource
#1Anzhelika Vorobyeva (Uppsala University)H-Index: 11
#2Ekaterina Bezverkhniaia (Tomsk Polytechnic University)H-Index: 1
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 10 authors...
Efficient treatment of disseminated triple-negative breast cancer (TNBC) remains an unmet clinical need. The epithelial cell adhesion molecule (EpCAM) is often overexpressed on the surface of TNBC cells, which makes EpCAM a potential therapeutic target. Radionuclide molecular imaging of EpCAM expression might permit selection of patients for EpCAM-targeting therapies. In this study, we evaluated a scaffold protein, designed ankyrin repeat protein (DARPin) Ec1, for imaging of EpCAM in TNBC. DARPi...
4 CitationsSource
#1Anzhelika VorobyevaH-Index: 11
#2Maryam OroujeniH-Index: 7
Last. Javad GarousiH-Index: 13
view all 8 authors...
Albumin binding domain-Derived Affinity ProTeins (ADAPTs) are small (5 kDa) engineered scaffold proteins that are promising targeting agents for radionuclide-based imaging. A recent clinical study has demonstrated that radiolabeled ADAPTs can efficiently visualize human epidermal growth factor receptor 2 (HER2) expression in breast cancer using SPECT imaging. However, the use of ADAPTs directly labeled with radiometals for targeted radionuclide therapy is limited by their high reabsorption and p...
1 CitationsSource
The object of the study was to analyze radionuclide detection techniques for in vivo animal imaging. Material and Methods. A total of 49 publications available from Scopus, Web of Science, Google Scholar eLIBRARY and Pubmed and published between 2013 and 2019 were reviewed. Results. The nuclear medicine techniques, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are the most suitable imaging modalities for in vivo animal imaging. Besides traditio...
Source
#1Javad Garousi (Uppsala University)H-Index: 13
#2Anna Orlova (Tomsk Polytechnic University)H-Index: 53
Last. Vladimir Tolmachev (Tomsk Polytechnic University)H-Index: 61
view all 4 authors...
The use of radiolabelled antibodies was proposed in 1970s for staging of malignant tumours. Intensive research established chemistry for radiolabelling of proteins and understanding of factors determining biodistribution and targeting properties. The use of radioimmunodetection for staging of cancer was not established as common practice due to approval and widespread use of [18F]-FDG, which provided a more general diagnostic use than antibodies or their fragments. Expanded application of antibo...
6 CitationsSource